What the UK guidance actually says
Doxy-PEP is the use of the antibiotic doxycycline as post-exposure prevention for some bacterial sexually transmitted infections. BASHH published its UK national guideline in 2025, for specialist sexual-health services. The earlier UK position that confined use to research is no longer a current summary. This guide was checked on 15 October 2026. A clinic must decide whether the guideline applies to a particular person; this article gives no dose, timing regimen or way to obtain the medicine yourself.
UKHSA's Syphilis Response Plan, updated 23 March 2026, describes delivery in England and says it will monitor uptake and impact and continue reviewing evidence for different settings and populations. Thus there is a national BASHH clinical recommendation for defined circumstances, alongside an evolving implementation and evidence review. Availability is not a promise that every clinic will prescribe it to every person. Ask your local sexual-health service about its current pathway.
Who the guideline considers
BASHH focuses on people at elevated risk, including gay, bisexual and other men who have sex with men and transgender women with recent bacterial STI diagnoses or multiple new partners, as UKHSA's 2026 plan summarises. The clinical guideline contains more nuanced eligibility and shared-decision considerations than an identity checklist. A clinician considers actual exposures, medical history, other prevention needs and the person's preference. Do not treat a label as an automatic prescription or as grounds to exclude someone without assessment.
The evidence is less established for some populations and types of contact. BASHH's 2025 review discusses limited evidence following receptive vaginal sex and found no protective effect in the trial of cisgender women that it assessed. UKHSA says evidence for other settings and populations remains under review. A person who does not fit a described group still deserves a sexual-health assessment and prevention advice; the answer may involve different tools rather than an unsupported extrapolation.
Understand the infections it may affect
BASHH frames doxy-PEP principally as syphilis prevention and reports evidence of reduced chlamydia in studied groups. It says protection is incomplete and that doxy-PEP is unlikely to prevent gonorrhoea reliably in the UK context. It does not prevent HIV, mpox or pregnancy. The PrEP and PEP guide explains HIV prevention; the mpox guide covers vaccination and symptoms. A person using one of these measures still needs appropriate STI tests and a conversation about condoms if relevant.
A new symptom or partner diagnosis should not be dismissed because doxy-PEP was used. The BASHH guideline recommends ordinary STI testing and management rather than assuming prevention replaces diagnosis or partner care. Tell the clinic about any use so that it can interpret the situation and plan follow-up. The testing guide explains why timing and site still matter. A negative test taken too early is not a certificate of protection.
Discuss benefits and harms with a clinician
Antibiotics can cause adverse effects and interact with a person's health or other medicines. BASHH discusses gastrointestinal and skin effects and a major uncertainty about antimicrobial resistance in both sexually and non-sexually transmitted bacteria. This is a public-health question as well as an individual one: widespread antibiotic exposure can affect future treatment. Do not use leftover antibiotics, a friend's prescription or an online regimen. A sexual-health clinician can explain the current evidence and whether individual contraindications matter.
Tell the clinician about pregnancy possibility, medicines, allergies and past reactions before any decision. The BASHH guideline includes clinical considerations for these circumstances; they are not instructions to decide eligibility yourself. Ask how the service will monitor STI diagnoses, review whether the intervention remains useful and respond to side effects. A choice can be revisited if partners or circumstances change. A medicine should not substitute for the care and information needed to make that choice.
Place it alongside other prevention
BASHH says doxy-PEP belongs in a wider prevention approach with condoms, HIV prevention, vaccination and regular STI testing. The NHS HIV page identifies PrEP and urgent PEP as different HIV medicines. Doxy-PEP is neither of those, despite the shared letters PEP. A sexual-health clinic can address several needs at one appointment, including testing and vaccination, rather than treating an antibiotic as a complete sexual-health strategy.
Consent and partner communication remain separate questions. Some people may want to discuss testing, barriers or symptoms with partners; nobody has to disclose a full medicine list to a casual acquaintance as a substitute for discussing the actual contact. The sexual health glossary and consent glossary provide starting definitions. If a partner has a diagnosed STI, ask the clinic about contact management even if you think a preventive medicine should have worked. Do not privately substitute it for prescribed treatment.
Follow changes in national policy
The source dates matter. The specialist BASHH guideline is dated 2025. UKHSA's plan was updated 23 March 2026 and applies to England. UKHSA explicitly says it will monitor implementation and continue to review evidence for other settings and populations. Check these pages and your nation's local service again when making a decision; this site was last checked on 15 October 2026.
Do not infer an identical funded pathway in all four nations from a UK-wide professional guideline. Ask a specialist sexual-health clinic in England, Scotland, Wales or Northern Ireland whether it provides doxy-PEP and under what clinical criteria. A service may instead prioritise testing, condoms, HIV prevention or vaccination. If an answer is unclear, request the current local policy or a clinician discussion. The changing evidence is a reason for clear review dates, not for an unsupervised trial.
Common questions about doxy-PEP
Is UK advice still “research only”? No; BASHH issued a UK clinical guideline in 2025. Is it for everyone? No; specialist assessment and evidence-based eligibility matter. Does it prevent all STIs? No. Does it replace HIV PrEP or urgent HIV PEP? No. Is it an antibiotic? Yes, which is why side effects and resistance matter. Should I use tablets already at home? No; speak to a sexual-health clinic.
Is the UK position still under review? Yes: UKHSA's March 2026 plan explicitly commits to reviewing evidence and delivery for other settings and populations. What if a partner has syphilis or I develop a sore? Contact a clinic for diagnosis and contact management; do not assume prevention settles it. Does a clinic need to know I have used it? Yes, that information helps interpret testing and plan care. Can I ask for another prevention plan if it is unsuitable? Yes.
UK routes to a specialist discussion
In England, locate an NHS sexual-health clinic and ask about its current doxy-PEP pathway. In Scotland, NHS inform directs people to local services; in Wales use NHS 111 Wales; in Northern Ireland use Sexual Health NI to find a GUM clinic. The clinic glossary explains the terminology. Availability and protocols may differ by nation and clinic; a professional guideline does not promise a service in each postcode.
Bring your STI history, exposure concerns and medicine list to a clinician, and ask about benefits, harms, testing and alternatives. If you have a possible recent HIV exposure, seek urgent HIV PEP assessment through a sexual-health service or A&E; doxy-PEP cannot replace it. For new symptoms or a known partner diagnosis, ask for STI assessment. The UK help directory provides additional routes. No dosage or self-prescribing directions are offered here.